COR Earnings Prediction
The chart below shows how COR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, COR sees a -2.63% change in stock price 10 days leading up to the earnings, and a -0.47% change 10 days following the report. On the earnings day itself, the stock moves by +1.42%. This data can give you a slight idea of what to expect for the next quarter's release.
COR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
81.49B
12.78%
3.08%
Gross Margin
2.78%
-7.33%
1.46%
Operating Margin
0.97%
-8.49%
14.12%
Net Margin
0.61%
-26.51%
6000.00%
EPS
2.50
-16.11%
12400.00%
No Data Available
COR Earnings Analysis
Cencora Inc Corporation (COR.N) Earnings Conference Call
Positive
Earnings Per Share Beat: Cencora reported adjusted EPS of $3.73, exceeding expectations of $3.50, marking a 14% increase year-over-year.
Healthcare Revenue Surge: Consolidated revenue reached $81.5 billion, reflecting a 13% growth primarily driven by the U.S. healthcare solutions segment.
Healthcare Solutions Revenue Growth: U.S. healthcare solutions segment revenue grew 14% to $74 billion, supported by strong prescription utilization trends and a 53% increase in GLP-1 product sales, which rose by $3.2 billion year-over-year.
Operating Income Increase: Consolidated operating income increased by 7% to $949 million, with the U.S. healthcare solutions segment contributing a 10% growth in operating income to $767 million.
EPS Guidance Increase: Cencora raised its full-year adjusted diluted EPS guidance to a range of $15.25 to $15.55, reflecting strong momentum in the U.S. healthcare solutions segment.
Negative
Gross Profit Margin Decline: Consolidated gross profit margin decreased by 20 basis points to 3.11%, primarily due to increased sales of low-margin GLP-1 products and lower sales of commercial COVID-19 vaccines.
Operating Expenses Increase: Consolidated operating expenses rose by approximately 6% to $1.6 billion, driven by higher distribution, selling, and administrative expenses, which could pressure future profitability.
Operating Income Decline: International healthcare solutions segment operating income declined by 3% on an as-reported basis, indicating challenges in maintaining profitability in this segment.
COVID-19 Vaccine Revenue Decline: The contribution from COVID-19 vaccines was about half that of the prior year quarter, with expectations for a similar operating income headwind in the second quarter of fiscal 2025.
Negative Adjusted Free Cash Flow: Adjusted free cash flow was negative at $2.8 billion due to timing issues, raising concerns about cash management and operational efficiency.
COR FAQs
How does COR typically perform around its earnings report dates?
Is Cencora Inc (COR) Q1 2025 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
COR Earning Call Sentiment
Cencora (NYSE:COR) Q1 2025 Earnings Call Transcript
COR.N
0.32%Positive
The earnings call presents a mixed picture. While financial performance showed growth, challenges like increased interest expenses, integration risks from the RCA acquisition, and deceleration in revenue growth were highlighted. The Q&A section revealed some management evasiveness, particularly around revenue deceleration and competitive pressures. Positive elements include strong EPS growth and share repurchases, but these are offset by concerns over vaccine sales decline and subdued clinical trial activity. Overall, the stock price is likely to remain stable, reflecting a neutral sentiment.
